This correspondence identifies actionable steps to advance CHIP–breast cancer research: external validation in diverse populations, temporality-sensitive analysis (landmark and time-varying exposure models), gene-level risk profiling (variant allele frequency, mutation class, co-mutations, polygenic risk adjustment), and biomarker-based assessment of inflammatory mediation to support risk-adapted prevention strategies. This evidence concerns the gene STUB1 and breast carcinoma.